Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Stroke outcomes

  • Home
  • Stroke outcomes
Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Insights from the TEMPO-2 Trial
Posted inEmergency Medicine Neurology news

Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Insights from the TEMPO-2 Trial

Posted by MedXY By MedXY 04/29/2026
Secondary analysis of TEMPO-2 trial data reveals intracranial hemorrhage in minor stroke patients increases 90-day mortality risk threefold, with higher hemorrhage rates in tenecteplase-treated patients despite most bleeds being non-symptomatic.
Read More
Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis
Posted inNeurology news

Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis

Posted by MedXY By MedXY 10/29/2025
A secondary analysis of the TEMPO-2 trial shows that intravenous tenecteplase does not improve 90-day outcomes in minor disabling stroke defined by NIHSS scores, highlighting the need to reconsider thrombolysis in this patient population.
Read More
  • Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention: The POINTER Imaging Ancillary Study
  • Thyroid Hormones May Offer a New Therapeutic and Prognostic Angle in ADPKD
  • Time-Restricted Eating vs Dietetic Guidance for Glycaemic Outcomes in Adults at Risk of Type 2 Diabetes
  • Gestational Diabetes and Later Cancer Risk: Reassuring Overall Results, but a Kidney Cancer Signal Emerges
  • Publicly Funded Intermittently Scanned Continuous Glucose Monitoring Is Linked to Fewer Hospitalizations in Insulin-Treated Type 2 Diabetes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in